7472-69-7

Usage

Uses

Used in Pharmaceutical and Biomedical Industries:
AKOS B013927 is used as a thickening agent for various formulations such as ointments, creams, and gels, enhancing their viscosity and stability.
Used in Food Industry:
AKOS B013927 is used as a stabilizing and texturizing agent, improving the consistency and texture of food products.
Used in Cosmetic Products:
AKOS B013927 is used as a stabilizing and texturizing agent, contributing to the product's consistency and improving its performance.
Used in Tissue Engineering:
AKOS B013927 is studied for its potential applications in tissue engineering due to its biocompatibility, supporting the growth and repair of tissues.
Used in Drug Delivery Systems:
AKOS B013927 is explored for use in drug delivery systems, leveraging its biodegradability to control the release of therapeutic agents and enhance treatment efficacy.

InChI:InChI=1/C10H11BrO3/c1-10(2,9(12)13)14-8-5-3-7(11)4-6-8/h3-6H,1-2H3,(H,12,13)

Upstream product

• 106-41-2 4-bromo-phenol 
• 67-66-3 chloroform 
• 67-64-1 acetone 
• 2052-01-9 2-bromo-2-methylpropionic acid 
• 75-25-2 Bromoform 
• 57-15-8 1,1,1-trichloro-2-methyl-2-propanol 

Downstream Products

• 59227-80-4 2-(4-bromophenoxy)-2-methylpropanoic acid ethyl ester 
• 5658-70-8 2-(4-bromophenoxy)-2-methylpropanamide 
• 61002-00-4 2-[(para-4'-fluorobenzoyl)-phenoxy]-2-methyl-propionic acid 
• 61161-19-1 2-{4-[Hydroxy-(4-nitro-phenyl)-methyl]-phenoxy}-2-methyl-propionic acid 
• 29941-94-4 2-(4-benzoylphenoxy)-2-methylpropanoic acid 
• 17431-97-9 2-(4-nitrophenoxy)-2-methylpropanoic acid 
• 124188-25-6 2-(4-bromo-2-nitrophenoxy)-2-methylpropanamide 
• 124206-54-8 2-(4-bromo-2-nitrophenoxy)-2-methylpropanoic acid 
• 124188-23-4 3,3-dimethyl-8-bromo-8-nitro-1,4-dioxaspiro<4.5>deca-6,9-dien-2-one 
• 49803-18-1 2-(4-bromophenoxy)-2-methylpropanoyl chloride 
• 229980-47-6 methyl 2-(4-bromophenoxy)-2-methylpropanoate 
• 1205683-43-7 C₁₂H₁₃BrN₂O₂ 
• 627095-94-7 2-(4-{2-[N-(heptyl)-N-(benzoxazol-2-yl)amino]ethyl}phenoxy)-2-methylpropanoic acid 
• 1350846-81-9 methyl 2-[4-(2-heptanoylaminoethyl)phenoxy]-2-methylpropanoate 

Relevant academic research and scientific papers

Discovery of a series of 1H-pyrrolo[2,3-b]pyridine compounds as potent TNIK inhibitors

In an in-house screening, 1H-pyrrolo[2,3-b]pyridine scaffold was found to have high inhibition on TNIK. Several series of compounds were designed and synthesized, among which some compounds had potent TNIK inhibition with IC50 values lower than 1 nM. Some compounds showed concentration-dependent characteristics of IL-2 inhibition. These results provided new applications of TNIK inhibitors and new prospects of TNIK as a drug target.

Exploration of a 14-3-3 PPI Pocket by Covalent Fragments as Stabilizers

The systematic discovery of functional fragments binding to the composite interface of protein complexes is a first critical step for the development of orthosteric stabilizers of protein-protein interactions (PPIs). We have previously shown that disulfide trapping successfully yielded covalent stabilizers for the PPI of 14-3-3 with the estrogen receptor ERα. Here we provide an assessment of the composite PPI target pocket and the molecular characteristics of various fragments binding to a specific subpocket. Evaluating structure-activity relationships highlights the basic principles for PPI stabilization by these covalent fragments that engage a relatively large and exposed binding pocket at the protein/peptide interface with a "molecular glue"mode of action.

PROTEIN-PROTEIN INTERACTION STABILIZERS

Provided herein, inter alia, are stabilizers of protein-protein interactions and methods of identifying and using the same.

Synthesis and preliminary antihyperlipidaemic activities evaluation of andrographolide derivatives

Recent studies indicated that andrographolide was a potential antihyperlipidaemic therapeutic agent. In the paper, the synthesis of a series of andrographolide derivatives was described and their antihyperlipidaemic activities were evaluated in vivo. As compared with TG, TC, HDL-C and LDL-C concentrations, some of the derivatives exhibited better antihyperlipidaemic effects than positive control atromide. Therein, compound 6i, which was the most potent compound, could serve as a new lead for further development of antihyperlipidaemic agents.

Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity

A series of ureidofibrate-like derivatives was prepared and assayed for their PPAR functional activity. A calorimetric approach was used to characterize PPARγ-ligand interactions, and docking experiments and X-ray studies were performed to explain the obs

NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES

[1,2,4]Triazolo[1,5-a]pyridine compounds are disclosed that have a formula represented by the following: (I) These compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g. diseases involving the anabolic stimulation of chondrocytes), congenital cartilage malformations, diseases associated with hypersecretion of IL6 and transplantation rejection (e.g. organ transplant rejection) and proliferative diseases.

CCR10 ANTAGONISTS

The invention relates to a compound of formula (I) or a tautomer thereof or a pharmaceutically acceptable salt thereof, wherein R1 to R11, W, X, Y, Z, and n are as defined herein. The invention also relates to methods of using the compounds of formula (I) and compositions thereof to treat various diseases and disorders in a patient. The invention also relates to processes for preparing the compounds of formula (I) and intermediates useful in these processes.

Liquid-phase synthesis of 2-methyl-2-aryloxypropanoic acid derivatives from poly(ethylene glycol) supported 2-bromo-2-methylpropanoate

An efficient liquid-phase synthesis of 2-methyl-2-aryloxypropanoic acid derivatives with good yields and high purity on soluble polyethylene glycol (PEG) has been developed by treatment of PEG-bound 2-bromo-2-methylpropanoate with phenoxides in the presence of a catalytic amount of NBu4I and KI, and subsequent cleavage from the PEG.

2-AMINOQUINAZOLINE DERIVATIVE

The present invention provides a compound represented by Formula (I) (wherein R 1 and R 2 are the same or different, and each represents a hydrogen atom, substituted or unsubstituted lower alkyl and the like, R 3 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group and the like, R 4 and R 5 are the same or different, and each represents a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl and the like, proviso that they are not simultaneously hydrogen atoms, and R 6 represents hydroxy or substituted or unsubstituted lower alkoxy), or a pharmaceutically acceptable salt thereof and the like.

INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION

There is provided a compound of formula: (I), wherein X, R1, R2, R3, R4, R5 and R6 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of microsomal prostaglandin E synthase-1 is desired and/or required, and particularly in the treatment of inflammation.